EICHORCondition: Chronic Lymphocytic Leukemia · Non-Hodgkin's Lymphoma · Sponsor: TG Therapeutics, Inc.
The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Confirmed B-cell non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and other B-cell lymphoproliferative disorders as approved by the Medical Monitor or Study Chair * Refractory to or relapsed after at least 1 prior treatment regimen * Eastern Cooperative Oncology Group (ECOG) score of 0 to 2 Exclusion Criteria: * Any major surgery, chemotherapy or immunotherapy within the last 21 days * Known hepatitis B virus, hepatitis C virus or HIV infection * Autologous hematologic stem cell transplant within 3 months of study entry or Allogeneic hematologic stem cell transplant within 12 months * Primary central nervous system lymphoma or known intracranial involvement
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| TG Therapeutics Investigational Trial Site | Huntsville, Alabama, United States | — |
| TG Therapeutics Investigational Trial Site | Jonesboro, Arkansas, United States | — |
| TG Therapeutics Investigational Trial Site | Duarte, California, United States | — |
| TG Therapeutics Investigational Trial Site | Atlanta, Georgia, United States | — |
| TG Therapeutics Investigational Trial Site | Omaha, Nebraska, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02006485